Skip to main content
Top

Drugs

Issue 11/2022

Content (9 Articles)

Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets

Federica Crispino, Mauro Grova, Erica Maria Bruno, Noemi Monachino, Giuseppe Rizzo, Angelo Casà, Sara Renna, Fabio Salvatore Macaluso, Ambrogio Orlando

Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy

Jonathan Golledge, Malindu E. Fernando, David G. Armstrong

New Developments in Glucagon Treatment for Hypoglycemia

LesleAnn Hayward Story, Leah M. Wilson

Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries

Swathi Pathadka, Vincent K. C. Yan, Chin Fen Neoh, Daoud Al-Badriyeh, David C. M. Kong, Monica A. Slavin, Benjamin J. Cowling, Ivan F. N. Hung, Ian C. K. Wong, Esther W. Chan

Desidustat: First Approval

Sohita Dhillon

Tirzepatide: First Approval

Yahiya Y. Syed

Tapinarof Cream 1%: First Approval

Susan J. Keam

Mosunetuzumab: First Approval

Connie Kang

Correction to: Mavacamten: First Approval

  • Open Access
  • Correction

Susan J. Keam

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images